LEADER 05286nam 22007572 450 001 9910784943703321 005 20160224031217.0 010 $a0-511-85021-2 010 $a1-107-20320-1 010 $a1-282-72332-4 010 $a9786612723322 010 $a0-511-74929-5 010 $a0-511-74349-1 010 $a0-511-75004-8 010 $a0-511-74242-8 010 $a0-511-75078-1 010 $a0-511-74458-7 035 $a(CKB)2670000000032440 035 $a(EBL)534728 035 $a(OCoLC)651599408 035 $a(SSID)ssj0000420429 035 $a(PQKBManifestationID)11286381 035 $a(PQKBTitleCode)TC0000420429 035 $a(PQKBWorkID)10392694 035 $a(PQKB)11082678 035 $a(UkCbUP)CR9780511750786 035 $a(MiAaPQ)EBC534728 035 $a(Au-PeEL)EBL534728 035 $a(CaPaEBR)ebr10406676 035 $a(CaONFJC)MIL272332 035 $a(EXLCZ)992670000000032440 100 $a20100412d2010|||| uy| 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aIncentives for global public health $epatent law and access to essential medicines /$fedited by Thomas Pogge, Matthew Rimmer, and Kim Rubenstein$b[electronic resource] 210 1$aCambridge :$cCambridge University Press,$d2010. 215 $a1 online resource (xxi, 512 pages) $cdigital, PDF file(s) 225 1 $aConnecting international law with public law 300 $aTitle from publisher's bibliographic system (viewed on 24 Feb 2016). 311 $a1-107-69345-4 311 $a0-521-11656-2 320 $aIncludes bibliographical references. 327 $aIntroduction: access to essential medicines: public health and international law / Thomas Pogge, Matthew Rimmer and Kim Rubenstein -- TRIPS and essential medicines: must one size fit all? Making the WTO responsive to the global health crisis / Rochelle C. Dreyfuss -- The TRIPS waiver as a recognition of public health concerns in the WTO / Andrew D. Mitchell and Tania Voon -- Public law challenges to the regulation of pharmaceutical patents in the US bilateral free trade agreements / Hitoshi Nasu -- Global health and development: patents and public interest / Elizabeth Siew Kuan Ng -- The Health Impact Fund: better pharmaceutical innovations at much lower price / Thomas Pogge -- The Health Impact Fund: a critique / Kathleen Liddell -- A prize system as a partial solution to the health crisis in the developing world / William W. Fisher and Talha Syed -- Innovation and insufficient evidence: the case for a WTO-WHO agreement on health technology safety and cost-effectiveness evaluation / Thomas Faunce -- Opening the dam: patent pools, innovation, and access to essential medicines / Dianne Nicol and Jane Nielsen -- Open source drug discovery: a revolutionary paradigm or a Utopian model? Krishna Ravi Srinivas -- Accessing and benefit sharing avian influenza viruses through the World Health Organisation: a CBD and TRIPS compromise thanks to Indonesia's sovereignty claim? / Charles Lawson and Barbara Ann Hocking -- The Lazarus effect: the (RED) campaign and creative capitalism / Matthew Rimmer -- Beyond TRIPS: the role of non-state actors and access to essential medicines / Noah Benjamin Novogrodsky -- Securing health through rights / Katharine G. Young -- The role of national laws in reconciling constitutional right to health with TRIPS obligations: an examination of the Glivec patent case in India / Rajshree Chandra -- Tipping point: Thai compulsory licenses redefine essential medicines debate / Jonathan Burton-MacLeod. 330 $aThis portrait of the global debate over patent law and access to essential medicines focuses on public health concerns about HIV/AIDS, malaria, tuberculosis, the SARS virus, influenza, and diseases of poverty. The essays explore the diplomatic negotiations and disputes in key international fora, such as the World Trade Organization, the World Health Organization and the World Intellectual Property Organization. Drawing upon international trade law, innovation policy, intellectual property law, health law, human rights and philosophy, the authors seek to canvass policy solutions which encourage and reward worthwhile pharmaceutical innovation while ensuring affordable access to advanced medicines. A number of creative policy options are critically assessed, including the development of a Health Impact Fund, prizes for medical innovation, the use of patent pools, open-source drug development and forms of 'creative capitalism'. 410 0$aConnecting international law with public law. 606 $aPharmaceutical policy 606 $aPatent laws and legislation 606 $aDrugs$xPatents 606 $aPatents (International law) 615 0$aPharmaceutical policy. 615 0$aPatent laws and legislation. 615 0$aDrugs$xPatents. 615 0$aPatents (International law) 676 $a362.17/82 702 $aPogge$b Thomas$f1953- 702 $aRimmer$b Matthew 702 $aRubenstein$b Kim 801 0$bUkCbUP 801 1$bUkCbUP 906 $aBOOK 912 $a9910784943703321 996 $aIncentives for global public health$93759139 997 $aUNINA